MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Cefazolin and Dextrose USP

Cefazolin and Dextrose USP


Company: B Braun Medical
Approval Status: Approved July 2000
Treatment for: Various bacterial infections, septicemia, endocarditis, and perioperative prophylaxis
Areas: Dermatology/Plastic Surgery; Immunology/Infectious Diseases; Nephrology/Urology; Pulmonary/Respiratory Diseases

| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |


General Information

Other Useful Resources

Cefazolin and Dextrose USP, for injection, has recently been approved using the Duplex drug delivery system, for the treatment of various bacterial infections. The multiple indications for this combination therapy include, but are not limited to respiratory tract infections, urinary tract infections, skin and skin structure infections, biliary tract infections, bone and joint infections, genital infections, septicemia (bloodstream infections), endocarditis (inflammatory disorder of the heart valves), and perioperative prophylaxis.

The administration of Cefazolin and Dextrose preoperatively, intraoperatively and postoperatively to patients undergoing high risk surgeries, such as a vaginal hysterectomy or to older patients at high risk of infection due to a compromised immune system, may decrease the occurance of certain postoperative infections.



< back to top

Clinical Results

In vitro tests have shown that the antibacterial action of Cefazolin is caused by the drug's inhibition of cell wall synthesis, therefore reducing bacterial cell growth.
Studies have also shown that in patients hospitalized with infection, Cefazolin administered intravenously has produced the same blood serum levels seen in healthy volunteers.



< back to top

Side Effects

Common side effects of Cefazolin and Dextrose for injection include, but are not limited to:

Gastrointestional reactions, including:
  • Diarrhea
  • Oral candidiasis
  • Stomach cramps
  • Anorexia

Allergic reactions, including:

  • Anaphylaxis
  • Eosinophilia
  • Itching
  • Drug fever
  • Skin rash
  • Stevens-Johnson Syndrome

Hematologic reactions, including:

  • Neutropenia
  • Leukopenia
  • Thrombocytopenia
  • Thrombocythemia

Some cases of Interstitial nephritis and other renal disorders have been reported rarely. In clinical trials, patients who experienced these side effects were seriously ill and were receiving multiple drug therapies. Transient hepatitis and cholestatic jaundice are also uncommon side effects associated with penicillin and cephalosporins.

Other rare side effects include genital and anal pruritis and rare instances of phlebitis at the site of injection.

Cefazolin and Dextrose injection is contraindicated for patients:

  • with known allergies to the cephalosporin group of antibiotics
  • with hypersensitivity to corn products
  • currently taking probenecid

Serious or fatal hypersensitivy has been reported in patients on penicillin therapy. Anaphalactic reactions are more likely to occur in patients that have a known history of sensitivity to multiple allergans.

Pseudomembranous colitis has also been reported and may range in severity from mild to life-threatening.



< back to top

Mechanism of Action

Cefazolin for Injection USP and Dextrose Injection USP is a sterile, nonpyrogenic (does not induce fever), single use, packaged combination of Cefazolin Sodium USP (lyophilized) and sterile iso-osmotic dilutant in the DUPLEX sterile container. (From FDA Label) It is administered through parenteral injection or intramuscular injection.



< back to top

Additional Information

While using Cefazoline USP and Dextrose USP diabetics may get a false-positive result when testing for sugar in their urine. Check with your doctor or a healthcare professional before changing your diet or your diabetic medication.

Pregnant women using Cefazoline USP and Dextrose USP should know that while the drug has not been shown to have harmful effects on the fetus, no adequate or conclusive studies have been done on Cefazoline use in pregnant women. The drug is present in trace amounts in the milk of nursing mothers. Nursing mothers should only use this drug when it is clearly necessary and prescribed by a physician.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.